0001209191-20-025937.txt : 20200428 0001209191-20-025937.hdr.sgml : 20200428 20200428162337 ACCESSION NUMBER: 0001209191-20-025937 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200424 FILED AS OF DATE: 20200428 DATE AS OF CHANGE: 20200428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Yuchun CENTRAL INDEX KEY: 0001334365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20825366 MAIL ADDRESS: STREET 1: 170 TRACER LA. CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-24 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001334365 Lee Yuchun C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2020-04-24 4 M 0 2000 57.27 A 3875 D Common Stock 2020-04-24 4 S 0 890 267.23 D 2985 D Common Stock 2020-04-24 4 S 0 590 268.31 D 2395 D Common Stock 2020-04-24 4 S 0 400 269.28 D 1995 D Common Stock 2020-04-24 4 S 0 120 270.30 D 1875 D Common Stock 2020-04-27 4 M 0 2000 57.27 A 3875 D Common Stock 2020-04-27 4 S 0 193 268.40 D 3682 D Common Stock 2020-04-27 4 S 0 394 270.37 D 3288 D Common Stock 2020-04-27 4 S 0 1113 271.56 D 2175 D Common Stock 2020-04-27 4 S 0 200 272.51 D 1975 D Common Stock 2020-04-27 4 S 0 100 273.44 D 1875 D Stock Option (Right to Buy) 57.27 2020-04-24 4 M 0 2000 0.00 D 2022-09-13 Common Stock 2000 3125 D Stock Option (Right to Buy) 57.27 2020-04-27 4 M 0 2000 0.00 D 2022-09-13 Common Stock 2000 1125 D Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $267.23 (range $266.72 to $267.71). Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $268.31 (range $267.94 to $268.77). Open market sales reported on this line occurred at a weighted average price of $269.28 (range $269.00 to $269.64). Open market sales reported on this line occurred at a weighted average price of $270.30 (range $270.05 to $270.33). Open market sales reported on this line occurred at a weighted average price of $268.40 (range $268.05 to $268.77). Open market sales reported on this line occurred at a weighted average price of $270.37 (range $270.08 to $270.78). Open market sales reported on this line occurred at a weighted average price of $271.56 (range $271.12 to $272.00). Open market sales reported on this line occurred at a weighted average price of $272.51 (range $272.31 to $272.71). Fully vested. /s/ Omar White, Attorney-in-Fact 2020-04-28